Abstract
Cell division cycle 25 (CDC25) phosphatases are key actors in eukaryotic cell cycle control. They are responsible for the dephosphorylations that activate the cyclin-dependent kinases (CDK) at specific stages of the cell cycle. Human CDC25A, CDC25B and CDC25C are also central targets and regulators of the G2/M checkpoint mechanisms activated in response to DNA injury. The expression and activity of these enzymes is finely regulated by multiple mechanisms including post-translational modifications, interactions with regulatory partners, control of their intracellular localization, and cell cycle-regulated degradation. Altered expression of these phosphatases is associated with checkpoint bypass and genetic instability. Accordingly, increased expression of CDC25A and CDC25B is found in many high-grade tumors and is correlated with poor prognosis in human cancers. This review summarizes our current knowledge within this domain and discusses the data that support therapeutic strategies targeting CDC25 activity in the treatment of cancer.
Keywords: Cell, CDC25 Phosphatases, eukaryotic cell, cyclin-dependent kinases (CDK), DNA injury, genetic instability, human cancers
Anti-Cancer Agents in Medicinal Chemistry
Title: Cell Cycle Control by the CDC25 Phosphatases
Volume: 8 Issue: 8
Author(s): Bernadette Aressy and Bernard Ducommun
Affiliation:
Keywords: Cell, CDC25 Phosphatases, eukaryotic cell, cyclin-dependent kinases (CDK), DNA injury, genetic instability, human cancers
Abstract: Cell division cycle 25 (CDC25) phosphatases are key actors in eukaryotic cell cycle control. They are responsible for the dephosphorylations that activate the cyclin-dependent kinases (CDK) at specific stages of the cell cycle. Human CDC25A, CDC25B and CDC25C are also central targets and regulators of the G2/M checkpoint mechanisms activated in response to DNA injury. The expression and activity of these enzymes is finely regulated by multiple mechanisms including post-translational modifications, interactions with regulatory partners, control of their intracellular localization, and cell cycle-regulated degradation. Altered expression of these phosphatases is associated with checkpoint bypass and genetic instability. Accordingly, increased expression of CDC25A and CDC25B is found in many high-grade tumors and is correlated with poor prognosis in human cancers. This review summarizes our current knowledge within this domain and discusses the data that support therapeutic strategies targeting CDC25 activity in the treatment of cancer.
Export Options
About this article
Cite this article as:
Aressy Bernadette and Ducommun Bernard, Cell Cycle Control by the CDC25 Phosphatases, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (8) . https://dx.doi.org/10.2174/187152008786847756
DOI https://dx.doi.org/10.2174/187152008786847756 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Silimarin and Cancer
Anti-Cancer Agents in Medicinal Chemistry Role of Androgen Receptor in Prostate Cancer Cell Cycle Regulation: Interaction with Cell Cycle Regulatory Proteins and Enzymes of DNA Synthesis
Current Protein & Peptide Science PD-L1 Inhibitors for the Treatment of Prostate Cancer
Current Drug Targets Leptin as a Novel Therapeutic Target for Immune Intervention
Current Drug Targets - Inflammation & Allergy Biological Evaluation of Azomethine-dihydroquinazolinone Conjugates as Cancer and Cholinesterase Inhibitors
Medicinal Chemistry Preface
Current Cancer Therapy Reviews Control of Melanoma Invasiveness by Anticollagenolytic Agents: A Reappraisal of an Old Concept
Anti-Cancer Agents in Medicinal Chemistry Anti-apoptotic Serpins as Therapeutics in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Neurobiological Influences on Recovery from Traumatic Brain Injury: The Role of Genetic Polymorphisms
Current Pharmaceutical Design Role of ABC Transporters in the Chemoresistance of Human Gliomas
Current Cancer Drug Targets Current and Emerging Treatments for Metastatic Renal Cell Carcinoma
Current Cancer Drug Targets The Design of Clinical Trials for New Molecularly Targeted Compounds: Progress and New Initiatives
Current Pharmaceutical Design Alzheimer's Disease: Emerging Trends in Small Molecule Therapies
Current Medicinal Chemistry Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Current Genomics 17α-Hydroxylase/17,20-Lyase (P450 ) Inhibitors in the Treatment of Prostate Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Gabapentin for the Treatment of Cancer-Related Pain Syndromes
Reviews on Recent Clinical Trials Molecular Imaging of Matrix Metalloproteinases In Vivo Using Small Molecule Inhibitors for SPECT and PET
Current Medicinal Chemistry γ-Secretase-Regulated Signaling Typified by Notch Signaling in the Immune System
Current Stem Cell Research & Therapy Translational Imaging of Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Target Recognition Molecules and Molecular Modeling Studies
Current Topics in Medicinal Chemistry